Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Diabetes Diabetes for November/December 2020 Sac/val heart failure benefit extends to diabetes patients, Don’t miss cardiovascular risk factors in transgender patients, Semaglutide shows promise in NASH phase 2 study, More must reads Diabetes for September/October 2020 Substance in tears could be used for diabetes monitoring, EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan, PPIs associated with diabetes risk, but questions remain, Dapagliflozin’s CKD performance sends heart failure messages, Higher glycemic time in range may benefit T2D patients, More must readsDiabetes for July/August 2020 Gut bacteria linked to cardiovascular, other health conditions, DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes, EMPEROR-Reduced: Empagliflozin's HFrEF benefit solidifies class effects, SGLT2 inhibitors with metformin look safe for bone, Diabetes plus weight loss equals increased risk of pancreatic cancer, More must readsDiabetes for May/June 2020 Diabetes-related amputations on the rise in older adults, Normal-weight prediabetes patients also benefit from lifestyle intervention, T2D plus heart failure packs a deadly punch, Dapagliflozin’s T2D renal protection extends to ‘fast decline’ of eGFR, Frequent hypoglycemic episodes raise cardiac event risk, More must readsDiabetes for March/April 2020 Metformin use linked to improved surgery outcomes, Inflammatory markers may explain COVID-19, diabetes dynamic, Use of diabetes technology is lower among black, Hispanic patients, Enhanced team-based CVD care found to benefit diabetes patients, Noninvasive fibrosis scores not sensitive in people with fatty liver disease and T2D, More must readsPages1 2 3 4 5 6 7 last »
